GILD vs AMGN
GILD and AMGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | AMGNAmgen Inc. |
|---|---|---|
| Market cap | $207.74B | $249.31B |
| P/E (TTM) | 24.7 | 28.6 |
| P/B | 15.93 | 21.33 |
| P/S | 7.1x | 6.8x |
| Dividend yield | 1.93% | 2.06% |
| Revenue | $30.99B(TTM) | $38.09B(TTM) |
| Revenue growth (YoY) | 2.4% | 10.0% |
| Net income | -$3.86B(TTM) | $8.74B(TTM) |
| Earnings growth (YoY) | 1672.9% | 88.5% |
| EPS, diluted | $-3.13(TTM) | $16.10(TTM) |
| EBIT margin | 34.0% | 24.7% |
| ROE | 65.3% | 66.0% |
| ROIC | 25.7% | 15.1% |
| 1y total return | +41.7% | +59.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs AMGN
| Metric | GILD | AMGN |
|---|---|---|
| End value | $28.3K | $40.5K |
| Total return | +182.8% | +305.2% |
| CAGR | +10.6% | +14.5% |
| Volatility | 25.6% | 25.1% |
| Sharpe | 0.36 | 0.50 |
| Sortino | 0.53 | 0.74 |
| Max drawdown | -30.5% | -24.9% |
Based on 2600 common trading days, 2016-07-01 → 2026-11-03 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)